AFTER: Application for the etonogestrel/ethinyl estradiol ring–potential for emergency contraception
Awarded 2017
Complex Family Planning Fellowship Research
Diana Crabtree Sokol, MD
University of Southern California

In order to investigate the ENG/EE CVR’s potential as a method of EC that provides ongoing contraception, we are proposing a pilot study to determine its ability to suppress ovulation when initiated in the late follicular phase. Our primary objective is to determine if the ENG/EE CVR has potential as a method of EC. We hypothesize that the CVR has potential, and will suppress ovulation or cause ovulatory dysfunction in the majority of participants within the 12-14mm and 15-17mm follicle groups.
The proposed study will be comprised of thirty-six healthy, non-pregnant, non-breastfeeding, reproductive age women with regular, ovulatory cycles who are protected from unintended pregnancy via the concurrent use of non-hormonal methods of contraception. Participants will have a mid-luteal screening visit, which will include: informed consent, history, physical, vitals, and assessment of mid-luteal serum progesterone to confirm ovulatory status. Participants will be assigned to one of three groups according the size of the leading follicle (12-14mm, 15-17mm, ≥18mm), which will determine the timing of the insertion of the ENG/EE CVR. Transvaginal ultrasound (TVUS) will be performed three times per week, starting on day 8 of the menstrual cycle, until the leading follicle is within the assigned group. On that day the CVR will be inserted and, including day of insertion, there will be 6 daily visits with hormonal assays (progesterone, luteinizing hormone) and TVUS to assess for signs of ovulation. Compliance with CVR insertion will be assessed through the measurement of serum ENG. After 7 days, the CVR will be removed and the participant will have biweekly visits until onset of menses to obtain serum progesterone levels and TVUS to confirm return to ovulation.

Skip to toolbar